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Quantum dots (QDs), an important class of emerging nano-
material, are widely anticipated to ﬁnd application in many
consumer and clinical products in the near future. Premarket
regulatory scrutiny is, thus, an issue gaining considerable
attention. Previous review papers have focused primarily on the
toxicity of QDs. From the point of view of product regulation,
however, parameters that determine exposure (e.g., dosage,
transformation, transportation, and persistence) are just as
important as inherent toxicity. We have structured our review
paper according to regulatory risk assessment practices, in order
to improve the utility of existing knowledge in a regulatory
context. Herein, we summarize the state of academic knowledge
on QDs pertaining not only to toxicity, but also their physico-
chemical properties, and their biological and environmental fate.
We conclude this review with recommendations on how to tailor
future research efforts to address the speciﬁc needs of regulators.
Key Words: ecotoxicology; toxicology; environmental fate;
regulatory policy; risk assessment; nanoparticles.
Quantum dots (QDs), an important class of emerging
nanomaterial, are ‘‘among the most promising items in the
nanotechnology toolbox’’ and are widely anticipated to
eventually ﬁnd application in a number of commercial
consumer and clinical products (Azzazy et al., 2007).
However, before QDs can enter the market, they will likely
be subjected to some form of regulatory scrutiny.
The type of regulatory scrutiny QDs will face is currently
unknown. Not a single jurisdiction in the world is presently
mandating the creation of speciﬁc safety-related data for
nanomaterials or has declared when and if such requirements
can be expected (Pelley and Saner, 2009). At the same time, it
is widely expected that nanomaterials, including QDs, will
face particular regulatory scrutiny at some point in the near
future.
The development of new regulatory requirements is an
iterative process. Regulatory data requirements (such as new
bioassays) can be a major impediment to innovation and will
not be mandated lightly. Instead, such requirements will be
developed once the existing scientiﬁc understanding suggests
that regulators require more information to assess environmen-
tal, health, and safety (EHS) risks. In the absence of speciﬁc
data requirements pertaining to EHS, regulators will have
limited access to new information. They will thus ﬁnd it
difﬁcult to arbitrate whether new regulatory measures will
lead to overregulation (through an excessive emphasis on
‘‘precaution’’) or if they are currently underregulating this class
of products. The chicken-and-egg problem is best managed by
maximizing the accessibility and utility of existing academic
knowledge in the regulatory context—which is precisely what
we set out to do.
Herein, we build on the seminal literature review on QDs
previously published by Hardman (2006). Hardman’s review
predominantly focused on the toxicity of QDs, however. This
is insufﬁcient in the regulatory context, as regulators require
knowledge of both the toxicity and the biological fate of
substances and products (including the absorption, distribution,
metabolism, and excretion (ADME) within a body, and the
transportation and transformation within the natural environ-
ment). In other words, it is not only the toxicity but also the
dosage, the likelihood of that dosage being administered, and
the concentrations in the natural environment that matter from
a risk perspective.
Aside from updating and reviewing data published since the
2006 review by Hardman, the main contribution of this paper is
that it summarizes what has been reported on the biological fate
of QDs in the academic literature to date. This approach
improves the accessibility of current academic knowledge on
QDs for risk assessors who are in the process of developing an
approach to the regulation of nanomaterials.
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according to the typical structure of a regulatory risk
assessment, as depicted in Figure 1 above.
What are QDs?
QDs, a heterogeneous class of engineered nanoparticles that
are both semiconductors and ﬂuorophores, are rapidly
emerging as an important class of nanoparticles with numerous
potential applications ranging from medicine to energy. In
terms of their basic structure, QD are nanocrystals composed of
a semiconductor core encased within a shell comprised of
a second semiconductor material. A typical QD has a diameter
in the range of 2–10 nm, which is comparable with the size of
a large protein.
For biomedical applications, QDs are generally solubilized
and require some form of biological ‘‘interfacing.’’ A number
of strategies for solubilization and imparting biofunctionality
have been devised; these have previously been reviewed by
Michalet et al. (2005). A single QD contains a large number
(10–100) of potential surface attachment groups, and therefore
can readily be conjugated to biomolecules such as biotin,
antibodies, oligonucleotides (DNA or RNA), or peptides
(illustrated in Fig. 2, below). A standard nomenclature is
generally utilized to describe the component parts of various
QDs, as follows: Core/Shell-Conjugate. For example, a QD
with a cadmium-selenium core and a zinc sulphide shell which
has been biotin conjugated would be designated as CdSe/ZnS
biotin.
Key Applications of QDs
The properties of QDs make them potentially useful in
a wide variety of settings, including electronics, computing,
and various biomedical and clinical imaging applications.
In the ﬁeld of electronics, researchers are looking to exploit
both the semiconductor and luminescent properties of QDs in
transistors, to build improved transistor capabilities. The
luminescent properties of QDs are being explored for use in
next generation versions of light-emitting diodes and diode
lasers. QDs are also being explored for potential applications in
the emerging ﬁeld of quantum computing.
The many potential biomedical applications of QDs have
been recently and extensively reviewed elsewhere (Azzazy
et al., 2007; Delehanty et al., 2008; Hild et al., 2008; Medintz
et al., 2008; Michalet et al., 2005; Jamieson et al., 2007;
Li et al., 2007; Samia et al., 2006). Biomedical applications
exploit the ﬂuorescent properties of QDs, and particularly their
advantages over traditional organic dyes, for both diagnostic
and clinical applications. The in vitro biomedical and di-
agnostic applications of QDs include such techniques as the
multicolor ﬂuorescent labelling of cell surface molecules and
cellular proteins in microscopy and other applications, de-
tection of pathogens and toxins, DNA and RNA technologies,
and ﬂuorescence resonance energy transfer. QDs are also being
explored for use in whole-body in vivo imaging of normal and
tumor tissues. QDs may also ﬁnd use in therapeutic
FIG. 1. The typical structure of a regulatory risk assessment.
FIG. 2. Basic structure of a QD.
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therapy, and drug discovery.
QDs VIEWED THROUGH A REGULATORY LENS
Governments have traditionally regulated novel technol-
ogies on the basis of speciﬁc products and their intended
uses (e.g., label claim), rather than on the basis of the
technology itself. The speciﬁc commercial applications of
QDs will therefore most likely dictate the approach to
regulation, and the perspective of regulators is best served if
QDs are classiﬁed in a way that is sensitive to the streaming
of novel products into existing regulatory frameworks. For
the sake of the discussion to follow, we break down the
heterogeneous category of all QDs into subcategories based
upon speciﬁc products or applications likely to be regulated
in a similar fashion. We propose the following three
regulatory classes of QDs. Note that the rudimentary
classiﬁcation scheme outlined below is intended to be
sensitive to the perspective of regulators without presuppos-
ing the future emergence of nanotechnology-speciﬁc regu-
latory approaches. It would be premature to be more speciﬁc
at this time because the regulatory system is currently under
development and because terminologies and nuances vary
internationally.
Class 1: Consumer products: QDs contained in consumer
products, particularly electronics and quantum computing
applications.
Class 2: Medical and imaging devices: QDs as in vitro
diagnostic agents and as imaging devices used in the
biomedical research setting.
Class 3: Pharmaceutical products: QDs as ‘‘nanomedicines’’
and in vivo diagnostic agents, that is, the use of QD in clinical
imaging and drug delivery applications.
Closely tied to the regulation of pharmaceutical products is
the regulation of food and food products. Any potential
applications for QDs in the area of food and food packaging
would likely be subject to a similar depth of regulatory
attention, if not increased regulatory scrutiny, as compared
with pharmaceuticals. Although we are not speciﬁcally aware
of any research being conducted into the use of QDs in food or
food packaging, a 2004 report reporting the use of QDs to
speciﬁcally detect a strain of Escherichia coli known be
a major cause of food borne illness (Su and Li, 2004) suggests
that QDs, like other nanoparticles, may eventually ﬁnd
applications in this area.
Beyond the three regulatory product classes of QDs
described above, one area in which the speciﬁc application of
a product does not currently dictate the approach to regulation
in a majority of jurisdictions is that of chemical substances.
The level of regulatory oversight for chemical substances
generally depends on a certain threshold concentration being
released into the environment.
In the sections that follow, we will discuss the physico-
chemical properties, toxicity, and biological fate of QDs in
sequence, according to the typical structure of a regulatory risk
assessment, as illustrated above in Figure 1.
BASIC PHYSICOCHEMICAL PROPERTIES OF QDs
The health and safety properties of QDs will largely be
dependent upon their basic physicochemical properties, such as
(1) chemical composition (purity and chemical make-up), (2)
shape and size (size may refer both to surface area and to size
distribution), and (3) surface properties and solubility (surface
reactivity, surface groups, inorganic or organic coatings, etc.).
This component of risk assessment requires attention because
the justiﬁcation for novel data requirements hinges to a large
extent on the unique behaviours exhibited by materials at the
nanoscale.
Chemical Composition
In terms of their chemical composition, QDs are a highly
heterogeneous group of products. QDs for biological applica-
tions, including those which are currently commercially
available from companies such as Invitrogen, are most
commonly comprised of cadmium and either selenium or
tellurium (CdSe and CdTe QDs) and are frequently coated by
a shell comprised of zinc sulphide (ZnS), but there are many
other possible combinations.
Cadmium, selenium, and tellurium all have known toxicities
in humans, including hepatic, renal, neurologic, and/or genetic
toxicities (reviewed in Bertin and Averbeck, 2006; Taylor,
1996; Vinceti et al., 2001). For this reason, it will be important
for regulators to know the exact chemical compositions of the
both the core and shell structures of the QD.
Size and Shape
The size, or hydrodynamic diameter (HD), of QDs can be
characterized by a variety of methods, including transmission
electron microscopy (TEM), dynamic light scattering, high-
solution atomic force microscopy and gel ﬁltration chroma-
tography. As will be discussed in further detail later, the HD
may be predictive of whether or not a particular QD will be
cleared from or retained in the body. As the HD of QDs will
vary considerably depending upon the organic coating
surrounding a QD core, it will be important to report the
HD for any new QD formulation undergoing regulatory
consideration.
Surface Properties and Solubility
QDs are not inherently water soluble—they are hydrophobic
by nature. It is therefore necessary to solubilize QDs for
applications in a biological environment by altering the surface
properties of the QD. Solubilization can be accomplished in
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silanization and surface exchange with bifunctional molecules
(i.e., molecules which possess both a hydrophobic side that can
bind to the shell of the QD, and a hydrophilic side that can
interact in an aqueous biological environment). For certain
applications, it may also be desirable to impart certain
functional properties upon the QDs. For example, if the QD
is to be targeted to a particular cell structure, cell type, or tissue,
then a targeting peptide or antibody may be attached to the
surface of the QD. As will be described below, the surface
composition and solubility properties of QDs can greatly affect
the toxicity and biological fate of QDs. Regulators will
therefore be interested in descriptions of the surface compo-
sition and measures of the solubility of individual QD
preparations.
TOXICITY OF QDs
With notable exceptions, the vast majority of scientiﬁc
papers reporting on the toxicity of QDs have limited their
investigations to cytotoxic effects of QDs observed in short-
term, cell culture-based assay systems, rather than addressing
the question of how QDs might affect the overall growth,
viability, and/or reproductive capacity of humans or other
species. Interpretation of the body of evidence relating to the
cytotoxic effects of QDs is further complicated as a result of
the broad diversity of QDs being tested, as each individual type
of QD possesses its own physicochemical properties and due to
the diversity of test systems used. The dosage of QDs used and
exposure times also vary widely in the literature. Furthermore,
it is often unclear how the experimental dosages relate to
concentrations associated with real-world commercial applica-
tions of QDs. It is therefore difﬁcult to extrapolate the results of
such studies in order to form any conclusions regarding the
health and safety of QDs. Nonetheless, these studies may
provide important insights that will be useful in guiding the
eventual design of standardized toxicity tests and protocols.
A Summary of Studies Assessing the Toxicity of QDs
In 2006, Ron Hardman authored a comprehensive review
regarding the toxicology of QDs and concluded that the
toxicity of QDs was dependent upon their physicochemical
properties as well as environmental factors (Hardman, 2006).
In this seminal review paper, Hardman included a table
summarizing the available literature concerning QD toxicity.
Below, in Table 1, we have adapted and extended
Hardman’s table to summarize studies that have been published
following acceptance of the Hardman review paper in
September 2005. We have attempted in this exercise to include
all relevant studies up to December 2008. For the sake of
completeness, the results of older studies, that is, those which
were originally reported by Hardman in 2006, are also
summarized below, in Table 2.
Discussions in the literature relating to the potential toxic
effects of nanotechnology applications often point to the fact
that the bulk forms of nanomaterials, many of which have been
in widespread use for many years, are themselves not toxic. As
an example, consider the case of carbon nanotubes, which are
nanoforms of carbon.
In the case of QDs, the situation is essentially reversed. The
bulk forms of some of the component molecules of QDs—such
as cadmium, selenium, and tellurium—are themselves known
to be highly toxic. The question therefore becomes one of
determining whether in nanoscale format (i.e., in the context of
QDs) the toxicity of these substances can be eliminated, or at
least drastically reduced.
In 2006, Hardman stated the following regarding the
toxicity of QDs: ‘‘QD size, charge, concentration, outer
coating bioactivity (capping material and functional groups),
and oxidative, photolytic, and mechanical stability have each
been implicated as determining factors in QD toxicity’’
(Hardman, 2006). Since 2006, a number of studies have
provided further support for this statement. This suggests that
the toxicity of QDs can, at least to some extent, be minimized
through selection of an appropriate shell coating (Cho et al.,
2007; Su et al., 2009), by modulating surface charge (Ryman-
Rasmussen et al., 2007) or surface coating (Guo et al., 2007),
by selecting a lower overall dosage of QDs (Tang et al.,
2008), or by modulating the overall size of the QD (Zhang
et al., 2007).
In a number of the toxicity studies summarized in Tables 1
and 2 below and particularly in earlier studies, the presence of
free cadmium ions in the QD preparations interferes with
extrapolation of the results regarding QD toxicity. This is
a major methodological issue which we note is generally being
addressed in more recent papers, either through the use of
highly puriﬁed commercially available QDs or by dialysing
QD preparations prior to their use in order to eliminate free
cadmium ions. However, although minimizing the presence of
free cadmium ions in QD preparations does seem to reduce the
toxicity of QDs, this alone does not explain all of the QD
toxicity reported in the literature.
Hardman (2006) stated that future research should attempt to
evaluate the long-term toxic effects of QDs, as ‘‘QD-induced
cytotoxicity was generally found in those studies that tended to
be longer in nature’’ (Hardman, 2006). This advice has not
been implemented—most of the recent studies (Table 1) relied
heavily on the use of short-term in vitro assays, most notably
the MTT (otherwise known as 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyl tetrazolium bromide) assay of cell viability.
We conclude that the progress on the evaluation of the
toxicity of QDs has only progressed marginally since Hardman’s
review. The most noteworthy changes from the perspective
of product regulation are the advances made in QD coatings.
Hardman’s call for long-term toxicity studies—which likely
would be echoed by regulators—remains unanswered by
current academic research.
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Summary of Quantum Dot Toxicity Studies Published from 2006 to 2008
Quantum dot
composition
Cell, tissue, or
organism tested Assay(s) used [QD] used Exposure time Observed toxicity Additional observations References
CdTe, CdTe/CdS,
CdTe/CdS/ZnS
K562 and HEK293T
human cell lines
MTT viability assay 0.2–3.0lM 0–48 h Cytotoxic: cells treated
with CdTe and CdTe/
CdS QDs were
mostly nonviable
by 48 h (for all
concentrations
tested).
ZnS shells may protect
from release of
cadmium ions and
resulting cytotoxicity.
(Su et al., 2009)
*QDs were
synthesized in
aqueous solution.
Not cytotoxic:i n
contrast, cells treated
with CdTeS/CdS/ZnS
QD showed no
cytotoxic effects up
to 48 h (16lMa t
24 h was also tested).
Authors postulate that
residual organic
solvents in
nonaqueous QD
preparations may have
resulted in QD-
independent cytotoxic
effects in other
reports.
*QD size was not
reported.
CdSe/ZnS-PEG
(EviTag T1
490 QD).
Caco-2 (human
colon carcinoma)
cell line.
MTT viability assay 0.84–105lM 0–24 h Commercially available
QD demonstrated
low cytotoxicity but
induced cell
detachment,
suggesting possible
toxicological effects
in the gastrointestinal
tract.
Acid treatment
(simulated gastric
ﬂuid) increased the
toxicity of PEG-
coated QD, likely by
inducing release of
free Cd ions by QD
degradation.
(Wang et al., 2008)
*Commercially
available QD.
*In vitro model for
small intestinal
epithelium (i.e., the
ingestion of QD).
Cell attachment
assay
CdSe Primary rat
hippocampal
neuron cells in
culture
MTT assay and DAPI
staining were both
used to assess
viability
1, 10, and 20nM 24 h Not cytotoxic: cells
treated with 1nM QD
for 24 h showed no
decrease in cell
viability.
Authors concluded that
CdSe QD induced cell
death of neurons in
a dose-dependent
manner.
(Tang et al., 2008)
*CdSe QD had a
HD of 2.38 nm.
Cytotoxic: in contrast,
cells treated with 10
and 20nM QD for
24 h showed
decreases in cell
viability on the order
of 20 and 30%,
respectively.
Authors also concluded
that CdSe QD could
induce dysregulation
of cytoplasmic
calcium levels in
neurons.
*QD were dialysed
prior to use to
remove free Cd ions.
CdTe; *red (6 nm),
yellow (4 nm),
and green (2 nm)
variants tested.
HepG2 (human
hepatoma) cell
line
MTT viability assay 0–100lM4 8 h Cytotoxic:
Concentrations
causing a 50%
reduction in MTT
activity were 19.1,
4.8, and 3.0lM for
red, yellow, and green
QD, respectively.
Smaller QD appeared
to be more cytotoxic
than larger QD in this
experimental system.
(Zhang et al., 2007)
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Quantum dot
composition
Cell, tissue, or
organism tested Assay(s) used [QD] used Exposure time Observed toxicity Additional observations References
*Preparations
contained free
Cd
2þ ions.
Free cadmium was at
least partially
responsible for the
observed QD
cytotoxicity.
CdTe (red in color;
6 nm diameter)
Intravenous
administration
into rats
Functional, locomotion,
and behavioral
measurements;
clinical chemistry;
urinalysis; and
histopathology
2mM solution; 1 ml/kg
administered (i.e., 2
lmol per kg body
weight)
0–24 h.
*0, 0.5, 1,
2, 4, 24-h time
points
A slight but signiﬁcant
reduction in body
weight was observed
in CdTe-treated rats
(vs. vehicle controls),
but few signs of overt
toxicity were noted.
Based on an observed
transient decrease in
locomotor activity
2-h post-treatment,
authors conclude that
nervous system
function may be
affected by QD.
(Zhang et al., 2007)
CdSe/ZnS QD of two
differing sizes and
shapes: QD-565
(4.6 nm spheres)
and QD-655 (6 3
12 nm ellipses)
coated with PEG
(neutral), PEG-amine
(neg. charge), or
polyacrylic acid
(pos. charge).
Primary neonatal
human epidermal
keratinocytes
(HEKs).
MTT viability assay
was used to assess
cytotoxicity.
0, 0.2, 2.0, and 20nM 24 and 48 h Cytotoxicity: Pos.
charged QD
demonstrated the
greatest cytotoxicity,
with a 20nM
concentration
resulting in
a signiﬁcant loss of
cell viability by 24 h
(both sizes of QD).
Authors conclude that
QDs with neutral
surface coatings are
signiﬁcantly less toxic
to skin cells (in some
cases, actually
nontoxic) than QDs
with positively or
negatively charged
surface coatings.
(Ryman-Rasmussen
et al., 2007)
*In vitro
model for skin
toxicity.
Low cytotoxicity:
Treatment of HEKs
with neg. charged QD
(both sizes at 20nM)
resulting in
a signiﬁcant loss of
cell viability at 48 h
only.
Authors also looked
at release of
inﬂammatory
cytokines by HEK
cells.
Very low cytotoxicity:i n
general, PEG-coated
QD had no effect on
cell viability, with the
exception that
treatment with 20nM
PEG-QD-655 resulted
in some loss of cell
viability at 48 h.
Inﬂammatory response:
only positively
charged QDs
signiﬁcantly induced
the release of
cytokines (IL-1b, IL-
6, IL-8).
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Quantum dot
composition
Cell, tissue, or
organism tested Assay(s) used [QD] used Exposure time Observed toxicity Additional observations References
CdSe incorporated in
PLA nanoparticles,
coated with F-68
(nonionic), CTAB
(neg. charge), or
SDS (pos.charge).
HepG2 (human
hepatoma) cell line
MTT viability assay 0–400 ppm 12–72 h Cytotoxic: all QDs
tested induced some
loss in cell viability,
with > 80% viability
upon treatment with
F-68 modiﬁed QDs.
This was in contrast
with treatment with
CTAB modiﬁed CdSe
QDs, where cell
viability was found to
be signiﬁcantly
decreased even at low
concentrations (10,
20, and 50 ppm) and
with incubations as
short as 12 h.
Authors conclude that
CdSe QDs modiﬁed
with F-68 have ‘‘low
cytotoxicity’’ based
on observation of 80%
or better cell viability
upon QD treatment.
(Guo et al., 2007)
Authors conclude that
surface modiﬁcation
with nonionic F-68 is
less cytotoxic than
modiﬁcation with pos.
charged CTAB.
*Size range was 159–
266 nm, which is
larger than the size
speciﬁed in most
deﬁnitions of
nanoparticles.
CdSe/ZnS-Cys, CdTe-
MPA, CdTe-Cys,
CdTe-NAC
MCF-7 (human breast
cancer) cell line
MTT and trypan blue
cell viability assays
10 lg/ml 1–24 h Cytotoxic: treatment of
cells with all forms of
CdTe QD resulted in
signiﬁcant cell death
at both 1 and 24 h.
Authors conclude that
CdTe QD are toxic
and that CdSe/ZnS
QD are nontoxic.
Authors demonstrate
release of free Cd ions
by CdTe QD but not
CdSe/ZnS QD.
Authors conclude that
CdTe QD induce cell
death via both Cd ion
dependent and
independent (ROS)
mechanisms.
(Cho et al., 2007)
Not cytotoxic: cells
treated with CdSe/
ZnS QD were mostly
viable after 24 h of
exposure.
CdSe/ZnS QD that
were both PEG-
coated and silanized
Human HSF-42 (skin
ﬁbroblast) and IMR-
90 (lung ﬁbroblast)
cell lines
Cell proliferation,
apoptosis, necrosis,
and cell cycle
distribution assays;
microarray analysis
0, 8, or 80nM (80nM ¼
40 mg/ml at M.W. of
500 kDa, or approx.
5 3 10
10 QD
per mm
3).
48 h Not cytotoxic: did not
see a decrease in cell
numbers or increased
apoptosis or necrosis
in cells at 48 h (slight
increase seen in skin
but not lung
ﬁbroblasts). Evidence
suggests only minimal
impact on cell health
and molecular
response of QD
exposed skin and lung
cells.
QD were internalized by
human skin and lung
ﬁbroblasts after 48 h
of exposure. Gene
expression of approx.
0.2% of genes was
signiﬁcantly different
in QD-treated skin
ﬁbroblasts versus
controls.
(Zhang et al., 2006)
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In this section, we will summarize the state of academic
knowledge up to December 2008 concerning the biological fate
(including ADME) of QDs.
For the purposes of the discussion to follow, we use the term
‘‘biological fate’’ to describe any number of the potential
outcomes that may befall QDs. We have deﬁned the term
broadly, so as to encompass: (1) potential routes of human
exposure to QDs; (2) the potential for the degradation of QDs
into their component molecules; (3) the tendency of QDs to
aggregate, which may affect their biological properties; (4) the
question of whether, once exposure has occurred, QDs will
accumulate in cells or tissues or whether they will be excreted
into the surrounding environment; and ﬁnally (5) the question
of what might happen to QDs following the excretion or release
into the environment. These issues will each be described in
detail in the sections that follow.
Potential Routes of Human Exposure to QDs
Central to a discussion of the toxicology and biological fate
of QDs is the question of what potential sources of exposure
might result in their uptake or absorption by humans. There are
a ﬁnite number of potential means by which humans can
theoretically become exposed to potentially toxic substances:
(1) if airborne, substances could potentially be inhaled; (2)
substances could be absorbed through the skin or eyes; (3)
substances could be ingested; or (4) they could be injected by
intravenous, subcutaneous or other injection methods. Below
we discuss these four potential routes of exposure and detail
and the state of current knowledge regarding the risk of human
exposure to QDs through each mechanism.
Quantum Dot Aerosolization and Inhalation
Assessing human exposure to airborne nanomaterials
represents a considerable challenge. As recently discussed by
Maynard and Aitken (2007), considerations such as particle
number, surface area, mass concentration and the basic
physicochemical properties of QDs will likely need to be
considered. The potential risks associated with the inhalation of
QDs are rarely, if ever, discussed. Whether this is due to the
fact that QDs do not readily become airborne or whether the
potential for aerosolization has simply not yet been evaluated is
unclear.
The greatest potential for aerosolization of QDs likely arises
during the synthesis and manipulation phases of QD
manufacturing, although we cannot rule out the possibility
that future clinical applications of QDs could be formulated as
aerosols. The conventional synthesis of QDs uses large
volumes of high-boiling organic solvents at high temperatures
into which aggressive and toxic chemicals must be quickly
injected. The synthesis of QDs using microwave irradiation (Li
et al., 2005) and chemical aerosol ﬂow synthesis (Didenko and
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Summary of Quantum Dot Toxicity Studies Published Prior to September 2005.
QD composition Cell, tissue, or organism tested [QD] used Exposure time Observed toxicity Reference
CdTe PC12 (rat pheochronocytoma)
and N9 (murine microglia)
cell lines
0.01–100 lg/ml 2–24 h Cytotoxic: 10 lg/ml (Lovric et al., 2005)
CdSe/ZnS-DHLA QDs B16F10 cells injected into
mice
Injected 20,000–40,000
QD-treated cells into
mice.
4–6 h cell incubation time,
mice sacriﬁced at 1–6 h
Not toxic: No toxicity
observed in cells or mice.
(Voura et al., 2004)
CdSe/ZnS-MUA Vero and HeLa cell lines;
primary human hepatocytes
0–0.4 mg/ml 24 h Cytotoxic: 0.2 mg/ml in Vero cells,
0.1 mg/ml in HeLa cells, 0.1 mg/ml
in hepatocytes.
(Shiohara et al., 2004)
CdSe/ZnS-SSA EL-4 cells (mouse lymphocytes) 0.1–0.4 mg/ml 0–24 h Cytotoxic: 0.1 mg/ml altered cell
growth; most cells nonviable at
0.4 mg/ml.
(Hoshino et al., 2004b)
CdSe/ZnS-SSA EL-4 cells labelled with
QDs and injected into
mice
0.1 mg/ml QDs per 5 3 10
7 cells 2 h to 7 days Not toxic: No toxicity observed
in mice in vivo.
(Hoshino et al., 2004b)
CdSe/ZnS conjugates:
NH2, OH, OH/COOH,
H2/OH, MUA, COOH
WTK1 cells 1–2lM 12 h Cytotoxic: 2lM QD-COOH induced
DNA damage at 2 h.
(Hoshino et al., 2004a)
CdSe-MAA, TOPO QDs Primary rat hepatocytes 62.5–1000 lg/ml 1–8 h Cytotoxic: A concentration of
62.5 lg/ml was cytotoxic
under oxidative/photolytic
conditions. No toxicity
observed on addition of ZnS cap
to QDs.
(Derfus et al., 2004)
CdSe/ZnS HeLa cells 10 pmol QDs per 10,000 cells
(approx. 10nM)
10 days (cell culture) Not cytotoxic: 10nM QD had
minimal impact on cell survival.
(Chen and Gerion, 2004)
CdSe/ZnS amp-QDs,
and mPEG QDs
Mice—QDs injected into
tail vein
Injections of approx. 180nM,
or 20 pmol/g animal weight
15-min cell incubations,
1–133 days in vivo
Not toxic: No signs of localized
necrosis at the sites of deposition.
(Ballou et al., 2004)
CdSe/ZnS-amphiphilic
micelle
Mice—QDs injected into
tail vein
60lM/gram animal weight,
1lM and 20nM ﬁnal [QD].
Not indicated. Mice showed no noticeable ill
effects upon imaging.
(Larson et al., 2003)
CdSe/ZnS-DHLA Dictyostelium discoideum
and HeLa cells
400–600nM 45–60 min No effects on cell growth noted. (Jaiswal et al., 2003)
Avidin-conjugated
CdSe/ZnS QDs
HeLa cells 0.5–1.0lM 15 min No effect on cell growth or
development noted.
(Jaiswal et al., 2003)
CdSe/ZnS-MUA QDs;
QD-SSA complexes
Vero cells 0.24 mg/ml 2 h Not cytotoxic: 0.4 mg/ml MUA/
SSA-QD complexes did not
affect the viability of Vero cells.
(Hanaki et al., 2003)
QD micelles: CdSe/ZnS
QDs in (PEG-PE)
and phosphati-dylcholine
Xenopus blastomeres 5 3 10
9 QDs/cell (approx.
0.23 pmol/cell)
Days Toxic: At a threshold of 5 3 10
9
QDs/cell, observed cell abnormalities,
altered viability and motility.
(Dubertret et al., 2002)
Note. PEG, polyethylene glycol.
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exposure to aerosolized QDs is an area that will require careful
consideration by regulators. We are not aware of any attempts
in the literature to date which address the potential effects of
inhaled QDs experimentally.
Absorption of QDs through the Skin and Eyes
The skin and eyes can both serve as portals of entry for
localized or systemic human exposure to potentially toxic
materials. Regulators will therefore want to know whether or
not it is possible for QDs to enter the human body through
dermal or ocular absorption, as well as the probability of
exposure to QDs through these routes.
In an in vitro study, Ryman-Rasmussen et al. (2006) have
reported that QDs are able to penetrate intact skin. According
to their results, QDs with different core/shell shapes (spherical
and ellipsoid) and sizes (4.6 nm in diameter and 12 3 6 nm)
and with variably charged (neutral, anionic, or cationic) surface
coatings were able to penetrate porcine skin within 24 h. In
terms of the generalizability of these results to real-world
setting, it is notable that the dosage of QDs administered in this
study (62.5 pmol/cm
2 of skin) was described as ‘‘occupation-
ally relevant’’ by the authors, and that porcine skin is
anatomically, physiologically, and biochemically similar to
human skin (Ryman-Rasmussen et al., 2006). We are not
aware of any in vivo studies on skin absorption nor any study
on ocular absorption of QDs.
Ingestion of QDs
To date, the possible toxicity of ingested QDs has not been
explored in any great detail. This may be due to the fact that at
present, there is little likelihood of QD applications under
active development being administered orally or incorporated
into food products or food packaging. Notwithstanding this,
regulators will need to understand the extent by which QDs
could accidentally be ingested by people who work in the
manufacturing industry, research laboratories, or diagnostic
facilities. Alternatively, QDs could also be ingested by eating
or drinking nanoparticle-contaminated food or water.
A recent report examined the possible toxic effects of ingested
QDs, using Caco-2 cells as model for the epithelium of the small
intestine. The authors of this report also examined the effect of
low pH, simulating conditions that would be encountered in the
human stomach, on CdSe QD cytotoxicity (Wang et al., 2008).
Exposure of QD to low pH conditions in this report resulted in
a loss of integrity of the QD structures, release of free cadmium
ions, and therefore an increase in QD toxicity. This evidence
demonstrates that the toxic effects of QDs could vary
considerably depending upon the route of exposure.
The Direct Injection of QDs into Humans
For the vast majority, if not all, of the potential applications
of QDs as in vivo nanodiagnostics and nanomedicines, QDs
will likely be administered through direct injection into humans
and animals. For applications such as sentinel lymph node
mapping in animal models, QDs would be injected directly into
tumor tissues, whereas intravenous injections are more likely in
other clinical applications. A number of studies have looked at
the ADME of injected QDs; these will be discussed in further
depth below. For the purposes of conducting risk assessments,
it will be important to specify the exact method of injection
(intravenous, subcutaneous, etc.), as recent reports have
suggested that the fate of QDs differs depending upon the
mode of injection.
A Summary of Studies Assessing the Biological Fate of QDs
Increasingly, researchers have begun to address the question
of what happens to QDs when they are administered in vivo.
Do QDs accumulate in tissues and if so, do they preferentially
become distributed in certain tissues versus others? Similarly,
is it possible to speciﬁcally target QDs to particular tissues?
This could be useful when using QDs as nanomedicines or in
vivo imaging agents; it might, for example, be useful to
speciﬁcally target tumor cells or affected lymph nodes in order
to either diagnose or treat cancer patients. Once administered,
are QDs eventually excreted, or do they tend to accumulate in
tissues? What is their half-life following administration? These
questions are all relevant to determining the ADME of QDs.
To provide a useful reference for regulators and researchers
alike, the results of studies addressing the biological fate of
administered QDs have been summarized in Table 3, below.
Two basic methodologies have been used in the literature to
examine the biological fate of QDs following in vivo
administration in lab animals. The ﬁrst methodology has taken
advantage of the ﬂuorescent properties of QDs; researchers
determine the biodistribution of QDs following administration
by tracking the ﬂuorescent particles. In this regard, QDs offer
a considerable advantage over many nanoparticles, in that their
luminescent properties render them highly suitable for studies
evaluating biological fate.
The second methodology involves generating radiolabeled
versions of QDs (e.g., CdTe QDs containing radioactive Te-
125m) and using these radioactive variants to track the
biodistribution of QDs. One advantage of the radiolabeling
methodology is that it allows for the derivation of quantitative
data regarding fate. On the other hand, the tracking of
radioactivity does not allow for distinguishing between QDs
which remain active and those that become inactive, including
those which have been degraded into their component
molecules. In contrast, only intact QD particles should continue
to ﬂuoresce.
As with toxicity, a number of studies have concluded that the
pharmacochemical properties of QDs including their size,
solubility, aggregation and surface composition may inﬂuence
the fate of the injected nanoparticles. For this reason,
a concerted effort has been made in Table 3 below to report
TOXICITY AND BIOLOGICAL FATE OF QDs 285TABLE 3
Summary of Studies Reporting the Biological Fate of QDs
Quantum dot
composition and
(emitting wavelength)
Hydrodynamic
diameter
Route of administration
and (model organism)
Duration of exposure
(and dose, if reported) Fate of QD Observations of in vivo toxicity Reference
CdSeS/silica-hydroxyl
(maximal emission
at 570 nm)
21.3 ± 2.0 nm Intravenous injection
(male mice)
0–5 days (5 nmol
per mouse)
- The plasma half-life of
QD was 19.8 ± 3.2 h.
Authors noted a lack of toxic effects
during the 5-day course of their
experiment, but acknowledged that
the long-term stability of the
CdSeS/SiO2 QDs in vivo remained
an unknown factor and that this is
an area that will require further
study.
(Chen et al.,
2008)
- The clearance of QD was
assessed at 57.3 ± 9.2 ml/h/kg.
- The liver and kidney were the
main target organs for QD, but there
accumulation was also noted in
spleen and lung. The peak
concentration of QD accumulation
occurred 6-h postinjection (peak
was 12 h in the lung).
- In this study, a fraction of free
QD was excreted via urine as small
molecules within 5 days.
- The majority of QDs bound to
protein and aggregated into larger
particles; these were metabolized in
the liver and excreted via feces.
- QDs in the spleen, lung, and kidney
were thoroughly eliminated within
48 h.
- After 5 days, 8.6% of the injected
dose of aggregated QDs remained
in the liver; it was difﬁcult for this
fraction to clear, indicating that
clearance of QDs was incomplete.
- By 1-h postinjection, the QD were
mostly cleared from the circulation.
- At the 1-h time point, QD conjugated
to a lung-speciﬁc mAb accumulated
primarily in the lung. QD not
targeted to the lung accumulated
primarily in the liver and spleen.
- By 24 h, lung-targeted QD had
redistributed to liver and spleen,
suggesting that they were being
taken up by cells of the RE system.
There was also an increase in
radioactivity in the kidney,
indicating excretion.
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RTABLE 3—Continued
Quantum dot
composition and
(emitting wavelength)
Hydrodynamic
diameter
Route of administration
and (model organism)
Duration of exposure
(and dose, if reported) Fate of QD Observations of in vivo toxicity Reference
- Temporary inhibition of the RE
system demonstrated involvement
of RE cells in clearance of QD from
lungs and redistribution to liver and
spleen.
CdTe/ZnS-mAb
(monoclonal
antibody (mAb)
targeted to lung).
Not reported Intravenous injection
(female mice)
1 h, 24 h, 7 days, 19
days
- Long whole-body
QD retention times were observed
(> 2 weeks).
In this study, it was not possible to
distinguish between any possible
toxic effects of the QD themselves
versus toxicity of the radiolabel,
therefore no conclusions could be
drawn regarding QD toxicity.
(Kennel
et al.,
2008)
*Radiolabeled with
Te-125m
CdSeTe/ZnS-methoxy-
PEG5000 (705 nm)
18.5 nm Intravenous
injection—tail vein (mice)
0–24 h, 1–28 days, and
6-month time points
(40 pmol)
No signiﬁcant excretion or metabolism
of QDs was observed in the 28 days
following dosing. QD were
concentrated in the spleen, liver and
kidneys.
Renal tissues, examined at 6 months by
TEM, showed proximal tubular
degeneration, indicating possible
toxicity. Changes in mitochondria
were particularly evident.
(Lin
et al.,
2008)
CdSe/ZnS 16 nm Injected
subcutaneously—right
anterior paw (mice)
0–24 h QD detected in lymph nodes within
minutes (~2.42% of total dose). Did
not detect QD migration to liver,
kidneys or spleen. Authors also
found no evidence of QD excretion.
Peak QD concentration in lymph
nodes detected at 60 min; fourfold
decrease seen by 24 h.
Toxicity was not assessed in
this study.
(Robe
et al.,
2008)
CdSe/ZnS-Cys size
series (515–574 nm).
4.36–8.65 nm Intravenous injection
(rats and mice)
0–4 h (100 llo f3 lM
99mTc-QD in mice;
in rats 10 pmol/g
animal weight)
- Radiolabeled QD with diameters of
4.36, 4.99, and 5.52 nm were found
to be excreted into the bladder
within 4 h.
Toxicity was not assessed in this
study—authors argue that in vivo
toxicity is less of an issue if QD are
excreted.
(Choi
et al.,
2007) *Zwitterionic surface
charge (Cys) found
to prevent serum
protein absorption;
this produced the
highest solubility
and smallest possible
diameter.
- QD larger than 5.6 nm were never
excreted, but instead were found to
be trapped in the liver, lung, and
spleen.
- The blood half-life of QD ranged
from48 minto20h,asthediameterof
QD increased from 4.36 to 8.65 nm.
CdSe/ZnS-PEG
(655 nm); and
CdSeTe/ZnS-PEG
(800 nm)
22.6, 30.4, and
41.2 nm
Injection into human
and mouse tumor models
(mice)
0–90 min. Animals
kept for up to 2
years (5–25 llo f
a preparation
containing 25–100
pmol QD)
Injection of QD into tumors yielded
rapid migration (within minutes)
into adjacent sentinel lymph nodes.
Authors state that the toxicity of amp-
coated CdSe/ZnS QD was minimal
or nonexistent for over 2 years, as
assessed by pathological
examination of animals.
(Ballou
et al.,
2007)
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Quantum dot
composition and
(emitting wavelength)
Hydrodynamic
diameter
Route of administration
and (model organism)
Duration of exposure
(and dose, if reported) Fate of QD Observations of in vivo toxicity Reference
CdSe/CdS-PEG
(621 nm)
37 nm Intradermal
injection—right dorsal
ﬂank (mice)
0–24 h Majority of QD remained at site of
injection. Detected QD in regional
lymph nodes within minutes. At
12–24 h, detected QD primarily in
the liver (~6% of total dose), lymph
nodes (~1%) and kidneys (~0.5%).
Also detected QD in spleen, hepatic
lymph node and heart (heart may
have been an artefact due to method
of animal sacriﬁce).
Toxicity was not assessed in
this study.
(Gopee
et al.,
2007)
CdTe/ZnS-PEG
(commercially
available QD705)
13 nm Intravenous injection
via tail veins (mice)
Up to 28 days: 1, 4, 24
h, 3, 7, 14, and 28
days (40 pmol per
mouse)
- Plasma kinetics revealed a clearance
rate from the blood of 2.3 ml/h/kg.
The plasma half-life was calculated
at 18.5 h.
- Tissues were subject to pathological
examination. This analysis revealed
marked sinusoidal congestion and
increased multinucleated giant cells
in vascular areas of the spleen.
Notably, liver and kidneys
displayed no remarkable
abnormalities.
(Yang
et al.,
2007)
- QD persisted in spleen, liver, and
kidneys throughout the
experimental period (up to 28 days).
QD levels in liver and kidneys
increased over time.
- QD were not detectable in feces and
were present only at low levels in
urine, indicating that essentially no
excretion occurred in 28 days.
CdTe/ZnS-DOTA
± peptide
(commercially
available QD705)
~20 nm Intravenous injection
(tumor-bearing
mice)
1-, 5-, 18-, and 25-h
time points
(20 pmol per mouse)
- Peptide conjugated
QD were speciﬁcally targeted to
tumors.
Toxicity was not assessed in
this study.
(Cai
et al.,
2007)
- For both peptide conjugated and
unconjugated QD, a majority of the
QD were found to localize to liver
(100:1), spleen (40:1) and bone
marrow (ratios represent tissue-to-
muscle ratios). To a lesser extent,
QD also localized to the kidneys
(1:1 ratio) and lymph nodes.
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Quantum dot
composition and
(emitting wavelength)
Hydrodynamic
diameter
Route of administration
and (model organism)
Duration of exposure
(and dose, if reported) Fate of QD Observations of in vivo toxicity Reference
CdSe/ZnS ± PEG
(commercially
available QD525
and QD800)
21 and 12 nm Intravenous
injection (mice)
0–15 min following
injection, then 1.0,
4.5, 12, and 36 h (25
pmol per mouse)
- The circulation time of PEG-coated
QD was 6 min (vs. 2 min for
uncoated QD).
- Authors comment that no evidence
of acute toxicity was observed
during and following the
experimental period. Authors also
comment that their data ‘‘suggest’’
that the QD exhibited good stability
in vivo, though they acknowledge
that no formal serum stability
studies were performed.
(Schipper
et al.,
2007)
- The major organ of uptake of QD
was liver; QD also found in spleen.
- Localization of QD to liver and
spleen was almost immediate
(within 2 min).
- Found that the size of the QD had no
effect on biodistribution, within the
size range tested in this study.
- Authors found no evidence of
clearance of QD from mice.
- PEG-coated QD also showed low-
level uptake to bone.
CdTe/ZnS-mAb
targeted to lung
Diameter not reported:
molecular weight
was 1–5 3 10
6 Da
Intravenous
injection (mice)
0–144 h - QD bound to a lung-speciﬁc
monoclonal antibody (mAb) were
effectively targeted to the lung and
remained in lung for up to 6 days.
Toxicity was not formally assessed in
this study, but authors noted that no
acute toxicity was observed.
(Woodward
et al.,
2007)
- QDs bound to a control mAb were
found to migrate primarily to the
spleen, liver, and kidneys.
- Authors observed that QD were
cleared from the body to a limited
extent, but that clearance was slow.
CdSe/ZnS-LM,
CdSe/ZnS-BSA
25, 80 nm Intravenous injection
(male Sprague-Dawley
rats)
10 days (5 nmol
dose per rat)
- QD half-lives were etermined to be
39–59 min; QD were cleared from
the plasma between 0.59 and 1.23
ml/min/kg.
Toxicity was not assessed in
this study.
(Fischer
et al.,
2006)
- By 90 min, approx. 90% of the BSA-
coated QD were found in the liver;
other tissues (spleen, lymph nodes,
bone marrow) also retained small
amounts.
- There were distinct differences
between the plasma clearance and
tissue distribution of uncoated and
BSA-coated QD.
- Authors could not detect QD in
either feces or urine, and therefore
concluded that the QD were not
excreted.
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Quantum dot
composition and
(emitting wavelength)
Hydrodynamic
diameter
Route of administration
and (model organism)
Duration of exposure
(and dose, if reported) Fate of QD Observations of in vivo toxicity Reference
InAs/ZnSe-DHLA-
PEG
8.7 nm Injected both
subcutaneously and
intravenously (in both
mice and rats)
Approximately 5 min - QD were speciﬁcally engineered to
have small diameters.
Toxicity was not assessed
in this study.
(Zimmer
et al.,
2006) - When injected subcutaneously, QD
migrated to sentinel lymph nodes,
as observed previously with larger
QD, but also migrated further into
the lymphatic system.
- QD injected intravenously were
shown to extravasate from the
vasculature (ﬁrst demonstration of
this point in the literature).
CdSe/ZnS-MAA-
targeting peptides ±
PEG (maximal
emission spectra at
both 550 and 625
nm)
In absence of peptide:
3 . 5n m( g r e e n )o r5 . 5
nm (red). Diameter
with peptide not
reported, but size was
approx. 190 kDa.
Intravenous injection
into the tail vein (mice)
5–20 min - QD were speciﬁcally targeted to the
circulatory systems of normal lungs
and tumors using peptides.
Toxicity was not assessed in
this study.
(Akerman
et al.,
2002)
- QD also accumulated in the liver and
spleen, regardless of the peptideused
for targeting.
- Adding PEG to the QD was shown to
partially inhibit the nonspeciﬁc
uptake of QD into the liver and
spleen (suggesting the involvement
of RE cells).
Note. PEG, Polyethylene glycol.
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including their chemical composition, emitting wavelength,
HD, and overall surface charge.
Of particular interest from a regulatory perspective, it has
been suggested that the HD of QDs may inﬂuence whether or
not they are excreted or will accumulate in tissues (Choi et al.,
2007). For this reason, we have included a column to report the
HD of the QDs under evaluation in each study.
We have also indicated the concentration, or dosage, of QDs
that was utilized in each study. Because dose-response
evaluations are a critical feature of the regulatory risk
assessment process, we were pleased to note that authors are
increasingly taking care to report the number of particles
administered (nmol and pmol), rather than the overall mass. In
some cases, authors have included observations of in vivo
toxicity in their reports; these have been summarized in Table 3
under the column heading ‘‘Observations of in vivo toxicity.’’
Results of studies to date have yielded certain commonalities,
but as yet there is no general agreement as to the fate of
administered QDs. This will be discussed below under the
sections on the accumulation and excretion of administered
QDs.
Accumulation of Administered QDs in Organ Tissues
Based on the results of a number of studies looking at the
biodistribution (and occasionally pharmacokinetics) of QDs
administered in vivo, it is possible to reach a few tentative
generalizations regarding the preference of QDs for accumu-
lation in certain target organs.
First, administered QDs are generally completely—and
likely also rapidly—cleared from the bloodstream. With
respect to the timing of clearance of QDs from the bloodstream,
estimates of the half-life of administered QDs in vivo vary from
one report to another. Interestingly, one report noted that the
blood half-life of a series of QDs varied considerably
depending upon the HD of the QDs; aside from varying in
terms of their size, the QDs in this series were otherwise
physicochemically identical in terms of their composition
(Choi et al., 2007). In this report alone, the blood half-life
varied from 48 min to 20 h—a rather wide range. However, all
of the reports in the literature were unanimous in concluding
that QDs show a preference for deposition in organs and tissues
and that they do not remain circulating in the bloodstream.
Second, QDs injected intravenously are more likely to
accumulate in the liver and spleen. To a lesser extent, QDs
injected in this fashion have also been detected in kidneys,
lymph nodes, and bone marrow. A subset of the reports
summarized in Table 3, for example the 2008 report by Kennel
et al. (2008), have attributed the observed migration to the liver
and spleen to clearance of QDs by phagocytic cells of the
reticuloendothelial (RE) system, which suggests that QDs
residing in organ tissues have already been internalized by
cells.
When QDs are injected either subcutaneously (Robe et al.,
2008; Zimmer et al., 2006), intradermally (Gopee et al., 2007),
or directly into animal tumor tissues (Ballou et al., 2007), the
pattern of organ deposition is different. QDs injected sub-
cutaneously or into tumors seem to migrate to nearby lymph
nodes and remain there. In the one study which looked at
intradermal injection, QDs were found in liver, lymph nodes,
and kidneys, but the vast majority of the QDs remained at the
site of injection. The results of Zimmer et al. (2006) suggest
that when the size, or HD, of QDs is above a certain threshold
limit (in their study, they estimate this threshold to be
approximately 10 nm), this may limit the ability of the QD
to migrate further into the lymphatic system or to extravasate
from the vasculature. Thus, a likely reason for the dependence
upon mode of injection on ﬁnal fate is that the scope of the
migration of QDs in vivo is effectively limited by their size.
It is worth noting that there are no reports to date describing
the migration of injected QDs into the brain. Whether this
means that QDs are incapable of crossing the blood-brain
barrier or whether they are simply cleared too quickly from the
circulation by cells of the RE system is a question which, to the
best of our knowledge, has not yet been assessed.
Excretion of Administered QDs
In their paper looking at the renal clearance of QDs, Choi
et al. (2007) posit that an analysis of bodily ﬂuids, including
urine, bile and feces, should be a mandatory part of any human
risk assessment following environmental exposure to nano-
particles. Provided that the initial exposure dose is known, such
an analysis could help to estimate the total retained dose of
nanoparticles.
To date, there have been a few studies in the literature which
have looked at the excretion of QDs following their in vivo
administration. Results to date have varied, and will be
described in further detail below.
Lin et al. (2008) performed in-depth pharmacokinetic and
toxicology studies in mice at time points of up to 6 months.
According to their results, commercially available Qtracker 705
nontargeted QDs (QD705) injected intravenously into mice
accumulated primarily within the liver, spleen, and kidney. The
authors could ﬁnd no evidence of excretion or metabolism of
the QD705 nanoparticles within 28 days following dosing.
Concerned by the persistence of the QDs, the authors examined
the kidneys by TEM at 6-months postdosing, and observed
signiﬁcant renal toxicity in the dosed but not control mice. The
‘‘subtle but deﬁnitive’’ cytological changes noted in dosed
mice consisted of proximal tubular degeneration, with pro-
nounced changes in mitochondria in the proximal convoluted
tubules. Based on these results, the authors caution that the
in vivo administration of QD705 may be highly toxic.
In contrast, other studies have demonstrated efﬁcient
excretion of QDs by mice. For example, Chen et al. (2008)
assessed the biodistribution and excretion paths of water
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were intravenously injected into mice. In contrast to the results
described above (Lin et al., 2008), in this study the majority of
injected QDs were cleared from mice, via both feces and urine,
within 5 days following injection. Only a small amount
(approximately 8.6%) of the injected QD dose was retained in
the mouse beyond the 5-day time point (although the authors
did comment that this remaining dose seemed to resist
clearance from the liver, where they seemed to accumulate).
Combined with the observed long-term stability of the silica
coated CdSeS QDs, the results of Chen et al. seem to indicate
few toxic effects linked to the in vivo administration of CdSeS
QDs in mice.
From a safety and regulatory perspective, the 2007 report by
Choi et al. (2007) opens an interesting avenue. This report
demonstrated that, for CdSe/ZnS QDs with a zwitterionic
charge and coated with cysteine, there appears to be a threshold
HD (in this case less than approximately 5.5 nm) below which
QDs are effectively cleared from the body through urine and
bile. The authors are justiﬁably cautious about overinterpreta-
tion of their results, pointing out that measurements of diameter
are inherently unreliable and therefore should not be
substituted in lieu of rigorous testing for clearance from the
body. However, these results suggest that it may be possible to
optimize QDs for biological applications in such a way as to
maximize their excretion from the body. Any toxic effects
associated with QD administration to a patient would thereby
be minimized. This does exclude, however, the potential of an
environmental impact during the subsequent environmental fate.
However, the next logical question becomes: what would
happen to QDs following their excretion from the human
body? What would be the possible effects of QD accumulation
in the environment following excretion? In this vein, the
ﬂedgling body of literature regarding the possible food chain
transfer and bioaccumulation of QD is summarized below.
Food Chain Transfer and Bioaccumulation of QDs
In a November 2008 report by the UK Royal Commission
on Environmental Pollution, the Commission noted that, with
respect to nanomaterials, ‘‘there is a consensus that mecha-
nisms of toxicity are poorly understood and that, with minor
exceptions, appropriate ecological studies have not been
undertaken, including studies that address food chain transfer
and multigenerational effects’’ (Royal Commission on Envi-
ronmental Pollution, 2008). It is therefore noteworthy that
among the ﬁrst reports to appear in the literature regarding the
ecotoxicity and food chain transfer of nanoparticles are three
publications pertaining to QDs (Bouldin et al., 2008; Gagne
et al., 2008; Holbrook et al., 2008).
In one report, the authors examined the toxic effects of
cadmium-telluride (CdTe) QDs on freshwater mussels (Gagne
et al., 2008). This study concluded that uncoated (i.e., no shell
structure) CdTe QDs were immunotoxic to freshwater mussels
within 24 h, leading to oxidative stress (lipid peroxidation) in
gills and genotoxicity (DNA damage) in the gills and digestive
glands. The toxic effects of uncoated QDs are well documented
in previous in vitro toxicity studies; this study supports the
observed in vitro toxicity of uncoated CdTe QDs in an in vivo
model of ecotoxicity.
Another report looked at the effects of commercially
available cadmium-selenium QDs coated with a ZnS shell
(Qdot 545 ITK Carboxyl QDs) on the freshwater alga
Pseudokirchneriella subcapitata and the cladoceran Cerio-
daphnia dubia (Bouldin et al., 2008). These model organisms
were selected by the authors ‘‘because they are established
model species in standard toxicological studies and ecological
risk assessments,’’ and because they ‘‘provide a simple model
for food chain transfer.’’ In this study, the authors found that
aquatic organisms exposed to QDs were able to withstand
concentrations of cadmium that were 500-fold or greater higher
than was the case for bulk cadmium. This result is contrary to
the widely held view that nanoforms of toxic materials (in this
case, cadmium) are likely to have toxicological effects at lower
concentrations due to their high surface area. Because in QDs,
the cadmium is encapsulated by a shell substance, the
nanoform of this substance appears to be overall less toxic
than its bulk counterpart.
High concentrations of the coated QDs tested in this report
were found to have lethal toxicological effects on freshwater
algae: the median lethal concentration of QDs on
P. subcapitata at 96 h was measured at 37.1 parts per billion
(ppb). No lethality was found following 48 h of exposure of
C. dubia to QDs at the highest concentrations tested (110 ppb),
which suggested that toxic cadmium from the QD core was not
bioavailable to the cladoceran species. One note of caution,
however, is that this study found that QDs could be transferred
up the food chain from dosed algae to C. dubia. Bioaccumu-
lation effects could therefore theoretically result in potential
exposure of higher order organisms to concentrations of QDs
beyond what could be achieved in this experimental system.
A third report looked at the effects of QDs in an invertebrate
rather than aquatic food chain, focusing on representative
bacteria (E. coli), ciliate (Tetrahymena pyriformis), and rotifer
(Brachionus calyciﬂorus) species (Holbrook et al., 2008). In
this simpliﬁed invertebrate food web, the authors did not
observe any signiﬁcant bioconcentration or biomagniﬁcations
of QDs. This study utilized commercially available ellipsoid-
shaped CdSe/ZnS QDs, and evaluated the effects of both
carboxylated and biotinylated QDs. In this experimental
system, there was no evidence of QD uptake by individual
E. coli bacterial cells. Both carboxylated and biotinylated QDs
could become attached to the exterior surface of aggregated
E. coli cells, but there was no evidence of ingestion of these
bacterial aggregates by the ciliates.
Despite the lack of trophic transfer from bacterial cells to
ciliates, the authors did ﬁnd evidence that QDs in aqueous
media could bioconcentrate in ciliate species. Both the
biotinylated and carboxylated QDs were taken up by the
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uptake), and biotinylated QDs were furthermore found to be
retained more than twice as long as carboxylated QDs. These
results suggest that physicochemical properties of QDs, such as
surface composition may modulate bioconcentration effects
(Holbrook et al., 2008). Trophic transfer of QDs between the
ciliates and rotifers was shown to occur, however the rotifers
were able to eliminate the QDs. Quantum dot half-lives in
rotifers ranged from 14.5 to 23.1 h and appeared to be
independent of surface chemistry. This result suggested that
although bioconcentration can occur in ciliate species,
bioaccumulation resulting from ciliate predation would not be
expected to occur in rotifers.
The three studies on the possible environmental effects
described above are clearly a step in the right direction. These
studies have shown the potential for bioaccumulation in aquatic
species, but no evidence of bioaccumulation in an invertebrate
food web. Further studies will be required in order to validate
and expand upon these preliminary results.
Stability and Aggregation
One component of fate that we have not yet discussed is the
potential for QDs to either degrade into their component
molecules (i.e., their stability) or to become transformed by
aggregation into higher order structures. In the section on
toxicity above, we noted that the degradation of QDs and
consequent release of free cadmium ions contributed to the
overall toxicity of QD. In their report evaluating the
biodistribution and metabolism of silica coated QDs, Chen
et al. demonstrated that the aggregation state of QDs in vivo
inﬂuenced their capacity to be excreted from the body, as well
as the path by which QD were metabolized (Chen et al., 2008).
From a regulatory perspective, the capacity for QDs to degrade
or become transformed is therefore of great importance. Below,
we will discuss factors which are known to inﬂuence the
stability and aggregation potential of QDs.
Woodward et al. (2007) recently assessed the chemical
stability of radiolabeled CdTe QDs in an aqueous environment.
When uncapped CdTe core QD were suspended in aqueous
buffer, approximately half of the radioactivity contained within
the QDs was released into the environment within 3 days. In
contrast, CdTe cores capped with a ZnS shell demonstrated
vastly increased stability. In fact, CdTe/ZnS QDs remained
stable in aqueous buffer for up to 36 days. This report suggests
that the capping of QDs with ZnS signiﬁcantly enhances their
stability in aqueous media.
Researchers have also begun to explore the potential effects
of pH on the overall stability of QDs. Chen et al. (2008) looked
at the effect of pH (pH 4.8 vs. pH 7.4) on the stability of
CdSeS/SiO2 QDs and found that these QD maintained their
integrity for up to 5 days in both high and low pH buffers. In
fact, they could not detect any leaching of free Cd ions from
CdSeS/SiO2 QDs, suggesting that these dots were extremely
stable in either pH environment. In contrast, Wang et al.
assessed the stability of commercially available polyethylene
glycol-coated CdSe/ZnS QDs and concluded that a low pH
environment led to a loss of QD integrity and release of free
cadmium ions (Wang et al., 2008). Thus the chemical
composition of QDs appears to be one factor which inﬂuences
the stability of QD in a low pH environment.
In a 2004 study, Derfus et al. (2004) demonstrated that
exposure of CdSe QDs to air and ultraviolet light led to the
degradation of the QD and the consequent release of free
cadmium ions. This in turn increased the toxicity of QD that
were exposed to air and UV light. The fact that air and UV light
can destabilize QDs may not be of particular signiﬁcance in the
context of QDs administered to humans, but it could become
a major factor when looking at the potential long-term effects
of QDs released into the environment.
Another factor that will be of signiﬁcant interest in terms of
predicting the fate of QDs will be the tendency of the dots to
aggregate into higher order structures. Several groups have
observed the aggregation of QDs under a variety of conditions.
For example, Zhang et al. (2007) recently assessed the stability
of CdTe nanoparticles under cell culture conditions and
observed the apparent agglomeration of red CdTe nanoparticles
over time. The authors additionally noted that this aggregation
of QDs was primarily extracellular. Another report looked at
the tendency of CdTe QDs to aggregate when dissolved in
aquarium water. In this study, it was observed that QD showed
a clear tendency to aggregate in the particulate phase, whereas
only approximately 15% of QDs were found in the dissolved
phase (Gagne et al., 2008). This study suggested that QDs in an
ecologically relevant aqueous environment may have a pre-
disposition toward aggregation.
The surface chemistry of various QDs will likely affect their
tendency to self-aggregate, and aggregated QDs may have very
different health and environmental effects than nonaggregated
particles. Research into the tendency of QDs to aggregate has
been limited to date; going forward, it will be important to
investigate the impacts of aggregation on the stability and
biological effects of QDs.
A more complete understanding of both the stability and
aggregation potential of QDs will be required in order to
further elucidate both the biological and environmental fates of
QDs.
FUTURE RESEARCH NEEDS FROM A REGULATORY
PERSPECTIVE
At this early stage in the commercial development of QDs,
the risk-relevant information available in the academic
literature is still limited. Below we will discuss some lessons
for regulators and researchers to keep in mind during the
iterative process that may (or may not) lead to speciﬁc
regulatory requirements for QD based products.
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a Substantial Regulatory Challenge
It is clear that the inherent toxicological potencies of various
QDs differ signiﬁcantly between various QD preparations. The
composition of the core, shell, and surface coatings, as well as
the overall size and shape of the QD may all impact upon the
toxicological proﬁle of different QD. As a result, some detailed
and completed case-by-case risk assessments will need to be
completed before any attempts at generalizing regulations across
a speciﬁc group or the full spectrum of QDs might become
possible. At this early stage, it is important that researchers
continue to report on as many of the properties of the QD
preparations that they are using in their studies as possible—this
will greatly facilitate any future attempts at generalization.
Regulators may want to think about incentives to promote this
knowledge transfer. Because of the real possibility that QDs can
become degraded, it will be additionally be necessary to report
not only on the properties of the overall QD construct, but
additionally its component molecules and concentrations. This
will be particularly important in the case of QDs which are
made up of substances like cadmium, selenium, and tellurium,
which have known toxicological properties.
Where Possible, Studies of the Toxicity, and Biological Fate
of QD Should Utilize Realistic Dosages
Researchers are making rapid progress in terms of un-
derstanding which factors (such as surface coatings and overall
size) can be manipulated in order to reduce the overall toxicity
of QDs and to improve the rate of their excretion from the
human body. Ultimately, however, regulators will be interested
in assessments of dose-response relationships. Admittedly,
because QDs are as yet still at an early stage in terms of the
development of commercial applications, it remains difﬁcult to
determine what might be realistic human and environmental
exposure levels. However, it remains important to report on
dosages and where possible, to utilize meaningful doses in all
experimentation. Without an estimation of realistic dose levels
to inform dose-response experimentation, it will not be possible
for regulators to carry out a meaningful risk assessment.
Toxicity Data to Date are Insufﬁciently Standardized and
based on too Few Endpoints
Research to date has been focused on in vitro assays of
cytotoxicity. In vitro studies are very important and can serve
as background information to inform the design of in vivo
studies, but on their own they provide an insufﬁcient basis for
a complete risk assessment. Once the relationship between
in vitro and in vivo assays of QDs is better understood,
however, regulators may ﬁnd great utility in rapid, cheap, and
highly standardized in vitro assays. We should note that there is
considerable pressure from European regulators to improve the
utility of in vitro studies and the ability to extrapolate from
in vitro to in vivo data in a regulatory context.
Cytotoxicity is an important starting point for beginning to
understand the biological effects of QDs, but it is not sufﬁcient
as a sole endpoint. For applications of QDs as diagnostic or
therapeutic tools, researchers are advised to carefully examine
the existing regulatory requirements for pharmaceutical
products. These requirements will provide important clues as
to which data points regulators may require in order to
complete a premarket regulatory risk assessment. The route of
administration and the doses used will be key considerations in
risk assessments. Data on the biological fate are also required
(see below). Studies in the literature have thus far tended to
focus on either toxicity or biological fate as endpoints. There
would be great merit, moving forward, in designing experi-
ments in such as way as to allow the simultaneous collection of
data on both toxicity and biological fate.
Toxicity studies to date have been conducted on a variety of
both human and nonhuman cells and cell lines, including the
studies described above in the section on the food chain
transfer and bioaccumulation of QDs. These data will be
helpful in estimating the variance in susceptibilities across
different species. Depending upon the location and quantities
of QDs that may be found to be released into the environment
and their environmental fate, regulators may require data on the
toxicity of QDs on indicator species (e.g., water ﬂeas are often
used in this context) or other species that are particularly
susceptible or exposed. Here, the existing regulatory require-
ments for the environmental assessment of pharmaceutical
products and the assessment of so-called ‘‘new substances’’
under Toxic Substances Control Act in the United States and
the Canadian Environmental Protection Act in Canada will
provide important clues for researchers about which endpoints
regulators may require in the assessment of QDs. The
Organization for Economic Co-operation and Development,
already an established leader for international testing protocols
for new substances, is also leading international efforts in the
standardization of regulatory protocols for nanomaterials.
Biological Fate Data are Insufﬁciently Standardized and
based on too Few Endpoints
Our literature survey has shown that the degradation of QDs
may be promoted by low pH, air, and ultraviolet light. The QD
shell and surface coating may be critical in preventing or
delaying this degradation process and, thus, the release of toxic
substances such as free cadmium ions from the QD core. This
fact will need to be taken into account in the design of studies
on toxicity and biological fate. Experimental data suggests that
uptake of QDs through the skin is a possible route of human
exposure. To date, very little or nothing is known about the
likelihood or possibility of QD entry through the eyes, nose or
mouth, or via inhalation or ingestion.
Administration of QDs by intravenous injection in model
animals has been shown to lead to accumulation of QDs in
tissues, and primarily in the liver and spleen. The rate of QD
accumulation in the human body will be of critical importance
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reported that QDs below a certain threshold size limit may be
efﬁciently excreted from the body whereas larger QD may
accumulate, deserve a great deal of regulatory attention. This
study in particular should be extended to examine alternate QD
formulations, compositions, and shapes, to help facilitate any
future generalizations regarding size thresholds in the regula-
tory context.
The results from a number of studies have indicated that the
placement of molecules such as proteins onto the surface of
QDs can greatly impact their pharmacokinetics and biodis-
tribution. Yet, in a number of the in vitro studies summarized
in Table 3, there have been no observations on whether
animal serum proteins are adsorbed to the surface of the
nanoparticles or whether the particles themselves are
becoming aggregated. The lack of these observations makes
it difﬁcult to compare studies, to understand cause-effect
relationships, and to link results from in vitro studies to those
observed in vivo.
Research examining the environmental fate of QDs has
just begun and interesting results have emerged. However,
the existing data on food chain transport, bioaccumulation or
biomagniﬁcation, and persistence in the natural environment
are as yet insufﬁcient to inform a complete environmental
risk assessment, even for those products that have been
tested. The extrapolation of the environmental risk assess-
ments of one QD to other products is, as mentioned above,
another step that will likely require additional data. We
should note, however, that the quantity of environmental
releases of QDs may eventually be found to be so limited
that regulators may judge a complete environmental
assessment to be a low priority.
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